- Results published in Vascular Medicine -
FREMONT, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, announced the publication of data supporting its peripheral artery disease (PAD) diagnostic program. The results were published in the August, 2008 issue of the peer-reviewed journal, Vascular Medicine. The study was led by John Cooke, MD, PhD, Professor of Medicine at Stanford University and involved researchers at Stanford, Mt. Sinai Medical Center (New York), and Vermillion.
"PAD is a serious disease that often goes undiagnosed and untreated," said Dr. John Cooke. "A blood test that identifies people at risk for this debilitating condition will improve diagnosis and give these people a better chance of getting the life- and limb-saving therapy they need. Our study indicates that this biomarker panel could assist physicians in identifying those individuals at highest risk of having PAD."
The study comprised 540 individuals: 197 individuals with both coronary artery disease and peripheral arterial disease (CAD + PAD); 81 with CAD only; and 262 with no hemodynamically significant disease (NHSD) of the coronary or peripheral arteries. Blood plasma was analyzed for a series of candidate biomarkers, and a final biomarker panel comprising Beta-2M, cystatin C, hsCRP, and glucose had an increased association with PAD status (odds ratio = 7.3).
Vermillion has entered into an exclusive license agreement with Stanford to develop and commercialize the PAD biomarker panel.
About Peripheral Artery Disease (PAD)
PAD, a serious but often asymptomatic disorder affecting some eight to
12 million Americans, is caused by the buildup of fat and c
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved